Waldenström's macroglobulinemia diagnostic study of choice: Difference between revisions
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
| Line 8: | Line 8: | ||
=== Diagnostic study of choice === | === Diagnostic study of choice === | ||
There is no single diagnostic study of choice for the diagnosis of Waldenström macroglobulinemia (WM), but [[bone marrow biopsy]] is considered to be mandatory for assessment of patients with WM and further followed by monoclonal protein studies.<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132 }} </ref><ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727 }} </ref> | There is no single diagnostic study of choice for the diagnosis of Waldenström macroglobulinemia (WM), but [[bone marrow aspiration and biopsy]] is considered to be mandatory for assessment of patients with WM and further followed by monoclonal protein studies called immunophenotyping and flow cytometry to distinguish WM from other types of B-cell lymphomas.<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132 }} </ref><ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727 }} </ref> | ||
=== Diagnostic results === | === Diagnostic results === | ||
Revision as of 14:28, 7 February 2019
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia diagnostic study of choice |
|
FDA on Waldenström's macroglobulinemia diagnostic study of choice |
|
CDC on Waldenström's macroglobulinemia diagnostic study of choice |
|
Waldenström's macroglobulinemia diagnostic study of choice in the news |
|
Blogs on Waldenström's macroglobulinemia diagnostic study of choice |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shyam Patel [3] Roukoz A. Karam, M.D.[4]
Overview
The diagnosis of Waldenström macroglobulinemia is based on bone marrow biopsy and serum protein analysis.
Diagnostic study of choice
Diagnostic study of choice
There is no single diagnostic study of choice for the diagnosis of Waldenström macroglobulinemia (WM), but bone marrow aspiration and biopsy is considered to be mandatory for assessment of patients with WM and further followed by monoclonal protein studies called immunophenotyping and flow cytometry to distinguish WM from other types of B-cell lymphomas.[1][2]
Diagnostic results
The following findings on performing bone marrow biopsy and serum protein analysis are confirmatory of Waldenström macroglobulinemia:[1]
- Presence of IgM monoclonal gammopathy on serum protein analysis (IgM can be of any size)
- A bone marrow biopsy demonstrating more than 10% infiltration by small lymphocytes with an intertrabecular pattern consistent with lymphoplasmacytic lymphoma
- Immunophenotype of the lymphoplasmacytic infiltrate consistent with Waldenstrom's macroglobulinemia. This includes: IgM+, CD5-, CD10-, CD11c-, CD19+, CD20+, CD22+, CD23-, CD25+, CD27+, FMC7+, CD103-
- Point mutation in the MYD88 gene (the L265P mutation)
References
- ↑ 1.0 1.1 Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
- ↑ Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R; et al. (2016). "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.